By Fineline Cube 
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced receiving clinical trial clearance from the National Medical Products Administration (NMPA) for its 20-valent pneumococcal polysaccharide conjugate vaccine. The vaccine is designed to prevent infectious diseases caused by 20 pneumococcal serotypes in children aged 2 months (minimum 6 weeks) to 5 years.
Vaccine Innovation and Coverage
This 20-valent vaccine represents an upgraded version of Walvax’s previously marketed 13-valent pneumococcal polysaccharide conjugate vaccine. It includes seven additional serotypes: 8, 10A, 11A, 12F, 15B, 22F, and 33F, in addition to the serotypes covered by the original 13-valent vaccine (types 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). This expanded coverage enhances the vaccine’s ability to protect against a broader range of pneumococcal infections.-Fineline Info & Tech